Latest Breaking News On - Med chief executive dayao zhao - Page 1 : comparemela.com

By Ben Glickman Shares of Ocular Therapeutix rose Tuesday after a trial of its drug Dextenza met its primary endpoint. The stock was up 15% to $2.85 in.

Ben glickmanDayao zhaoOcular therapeutixAmed therapeuticsMed chief executive dayao zhaoArticle normalHealthcare life sciencesSpecialized drugs medicationsFinancial performanceShare price movement disruptionsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingEquity markets